The renowned columnist from Harvard Business Review, Stefan Tomke, once pointed out: “There is a fundamental contradiction in today’s world: the economy increasingly relies on services, yet the innovation process remains product-oriented. While there are numerous methods for scientific product development and improvement, there is no strict and continuous service development process.†This insight has become a guiding principle for the biomedical industry in Beijing.
**R&D Services: The Road to China’s Biopharmaceutical Industry**
According to statistics, the biomedical R&D service industry originated in the United States in the early 1980s. As U.S. pharmaceutical regulations improved, new drug approvals became more rigorous, leading to higher R&D costs and longer timelines. To survive and thrive in a competitive environment, pharmaceutical companies began outsourcing parts or all of their R&D processes to specialized research organizations, aiming to boost efficiency, reduce costs, and mitigate risks. This gave rise to the R&D service industry. Over time, the industry evolved into three main categories: R&D planning, project execution, and result delivery, covering the entire biomedical R&D lifecycle.
Similarly, China's biomedical sector faces the challenge of developing a robust service system tailored for R&D. With the global division of labor becoming more refined, the innovation chain in new drug development has expanded significantly. To achieve optimal resource allocation, the R&D process has been fragmented and assigned to different specialized agencies. In other words, the creation of a new drug is no longer the work of a single institution but the result of collaboration among multiple professional entities. This shift has embedded the R&D service industry deeply into every stage of the R&D value chain, making it an essential component of the innovation ecosystem.
Under the leadership of the Beijing Municipal Science and Technology Commission, the "industry-based ties" innovation alliance has moved beyond supporting individual enterprises and projects. This evolving mechanism and strategy have driven significant reforms in the biopharmaceutical industry.
Based on institutional innovation, the commission recognized that the development of the biomedical R&D service industry is a key indicator of a region's capacity for new drug creation. It plays a vital role in the innovation chain and serves as a foundation for an enterprise-driven drug development system. The commission believes that the maturity of the R&D service industry directly impacts the overall progress of drug discovery in Beijing and across China.
Guided by this vision, the Beijing Science and Technology Commission launched the China Biotechnology Outsourcing Service Alliance (ABO Alliance), bringing together domestic and international service-oriented enterprises and R&D institutions. The ABO Alliance aims to build a complete service chain, engage with multinational companies, enhance competitiveness, and participate in the global division of labor.
Currently, the ABO Alliance is one of the driving forces behind the restructuring of China’s biopharmaceutical industry. Ten years ago, the sector was heavily reliant on manufacturing. Now, in cities like Beijing and Shanghai, the integration of manufacturing and services is emerging. According to Zhang Zegong, deputy director of the Beijing Biotechnology and New Pharmaceutical Industry Promotion Center, Beijing benefits from its advanced scientific resources, rich clinical data, and a centralized drug administration system, giving it a unique advantage in developing medical R&D services. As a national innovation hub, Beijing has become a model for the rapid growth of the pharmaceutical R&D service industry.
Beijing's biopharmaceutical sector has entered a new phase of service development. Annual revenue from biomedical R&D services has exceeded 5 billion yuan. The city has developed capabilities in clinical trial services, preclinical research, and new drug development and transfer. However, despite these achievements, most R&D service companies in Beijing are still at an early stage, with limited scale and some proprietary technologies.
To foster industrial growth, the Beijing Science and Technology Commission supports the standardization of the ABO Alliance and helps integrate it into the global market. The alliance aims to improve R&D efficiency, expand the biomedical R&D service industry, and promote industrial restructuring. Its goal is to create a unified standard, share brand value, and offer "one-stop" solutions to customers. Over the past three years, the ABO Alliance has supported global innovation activities and integrated SMEs, the most dynamic players in the innovation chain.
Today, the ABO Alliance has grown from 8 to 28 members, including 3 internationally accredited labs, 3 GLP facilities, 4 GMP workshops, and 1 applying for FDA certification. It also houses three major incubators and an internal support platform offering lab management systems, instrument analysis, information technology, and talent training. The alliance has partnered with several top institutions, providing genome-related services, antibody and protein solutions, drug safety evaluations, and more.
At the Twelfth Bio-pharmaceutical Industry Development Forum, the ABO Alliance showcased Beijing's strength in biomedical R&D services, promoting the industry's rapid growth. Since its inception in 1997, the forum has become a key platform for China's biopharmaceutical sector, guiding its development and setting industry benchmarks.
Over the years, the forum has highlighted trends such as CRO concepts, global R&D shifts, and China's growing role in the international pharmaceutical landscape. With the theme "One World, Unified Standards," the forum aims to integrate China’s biopharmaceutical industry into the global innovation chain.
Through these efforts, Beijing has emerged as a leader in the biomedical R&D service industry, gaining recognition on the global stage. Companies like Kanglong Huacheng and Yingxin Taikang exemplify the rapid growth and innovative strategies driving the sector forward. With its unique advantages and strong development momentum, Beijing continues to shape the future of China’s biopharmaceutical industry.
Heat Pump For Agriculture
Introduction to GENT heat pump for agriculture
The classification of agricultural heat pumps is divided according to the standard of heat pump usage scenarios. Agricultural heat pump refers to heat pump units that can be used in the agricultural field.
Heat pump systems have a wide range of application potential in the agricultural field. Their high efficiency, energy saving and environmental protection make them an ideal alternative to traditional heating/cooling methods. Many of GENT's units can be applied to the agricultural field to meet the needs of indoor space cooling, heating, constant temperature, drying, etc. in the agricultural field.
Applicable scenarios
Heat pump units are suitable for multiple agricultural scenarios, including:
1. Greenhouse planting
Heat pump for greenhouse can provide stable temperature and precise temperature control in greenhouses. Using heat pump units to complete greenhouse temperature control can achieve precise temperature control, improve the growth rate and quality of crops, and effectively reduce dependence on fossil energy and reduce carbon emissions.
2. Drying of agricultural products
High Temperature Air Source Heat Pump can replace traditional coal/fuel drying equipment to achieve the drying of agricultural products such as grains, fruits and vegetables, and medicinal materials. The drying quality of agricultural products dried by heat pump units is high, in line with food hygiene standards, and the operating cost of this drying method is 30%~50% lower than that of traditional electric heating.
3. Hot water supply
Heat pump for farm can provide hot water for washing, disinfection and drinking in agricultural scenes, reducing energy consumption and livestock morbidity.
4. Livestock breeding
Heat pumps in agriculture can provide winter heating (such as piglet insulation) and summer cooling for livestock and poultry houses, improving the breeding environment. This can effectively reduce the cold stress of livestock, increase survival rate and meat/egg production, and is safer than burning coal and can effectively avoid the risk of carbon monoxide poisoning.
5. Aquaculture
Heat pump units can effectively regulate the water temperature of aquaculture, keep the water temperature in the appropriate range of 20~30°, and shorten the breeding cycle. In addition, if conditions permit, heat pumps can be combined with waste heat recovery systems to further improve energy efficiency.
It can be seen that the application of heat pump units in the agricultural field is feasible and has a very wide application market. Therefore, agricultural users with corresponding needs can consider using GENT's high efficiency heat pump. You are welcome to communicate with us for consultation.
Agricultural Heat Pumps,Heat Pumps in Agriculture,high efficiency heat pump,heat pump systems,heat pump for farm
GUANGZHOU GENT NEW ENERGY TECHNOLOGY CO., LTD , https://www.gentgz.com